Coactivators PGC-1β and SRC-1 Interact Functionally to Promote the Agonist Activity of the Selective Estrogen Receptor Modulator Tamoxifen*

PGC-1β is a transcriptional coactivator that enhances strongly and in a hormone-dependent manner the activity of the estrogen receptor α (ERα) while having only weak effects on similar steroid hormone receptors, such as ERβ or the glucocorticoid receptor. Notably, PGC-1β enhances ERα transcriptional activity not only in response to agonist ligands, such as estradiol, but also to selective ER modulators, such as tamoxifen. Here, we dissect the molecular mechanisms underlying the ability of PGC-1β to act selectively on ERα and to promote the agonist activity of tamoxifen. We show that receptor selectivity is achieved by PGC-1β interactions with not just the ligand binding domain (LBD), which is highly conserved among nuclear receptors, but also the N-terminal domain and the hinge/AF-2a region of ERα, which are less well conserved. PGC-1β interacts directly with the hinge/AF-2a and LBD regions but indirectly and via the coactivator SRC-1 with the N-terminal domain. The three ERα surfaces and SRC-1 collectively enable efficient coactivation by PGC-1β. Similar ERα surfaces and interactions enable PGC-1β to coactivate transcription by tamoxifen-bound ERα. Surprisingly, PGC-1β coactivation of tamoxifen-bound ERα depends partially on one of the LXXLL motifs of PGC-1β and on Lys362 of the ERα LBD (i.e. surfaces implicated in agonist-dependent interactions). Our findings suggest that tamoxifen-induced changes in the ERα LBD promote interactions with the coactivator PGC-1β, which then cooperates with SRC-1 to enable tamoxifen agonism.

Estrogens play important roles in the female reproductive system and impact on the physiology of a broad range of nonreproductive systems, including bone, the cardiovascular and central nervous systems, and glucose and lipid metabolism (1)(2)(3). Estrogens also exert proliferative effects on hormoneresponsive breast cancers (i.e. ϳ50% of breast cancer cases). The action of estrogens is mediated by two estrogen-regulated transcription factors that belong to the nuclear receptor family, and are referred to as estrogen receptors ␣ and ␤ (ER␣ and -␤) 3 (2,4). Because ligand-activated ERs promote beneficial effects in some contexts, such as bone density maintenance, and harmful effects in others, such as the proliferation of breast cancer cells, there is a clinical interest in synthetic ER ligands that act as agonists in some tissues and antagonists in others. Such selective estrogen receptor modulators (SERMs) (e.g. tamoxifen) are used to treat estrogen-responsive breast cancers, where they antagonize endogenous estrogen action while maintaining beneficial agonist effects in bone and the cardiovascular system (1,5). The cellular factors that determine the agonistic versus antagonistic properties of tamoxifen and other SERMs are only partially understood (5,6). These factors are likely to be important not only for determining the tissue selectivity of SERM action, but also for understanding how breast cancers eventually develop resistance to treatment and start recognizing tamoxifen as an agonist that promotes proliferation (5).
ER␣ has the typical modular structure of nuclear receptors (4). A central DNA binding domain (DBD) mediates recruitment to specific DNA sequences, termed estrogen response elements (EREs). A C-terminal ligand-binding domain (LBD), separated from the DBD by a short hinge region, serves as the molecular switch that conveys information on the presence and type of ligand. Ligand-activated, DNA-bound ER␣ regulates the expression of genes via two transcriptional activation functions, denoted AF-1 and AF-2. AF-1 is located in the N-terminal domain of ER␣, a region that is not conserved among different nuclear receptors and can activate transcription in a ligand-independent manner. AF-2 is encoded by highly conserved parts of the LBD and is tightly regulated by ligand. The ability of different ER␣ ligands to act as agonists or antagonists relies largely on their ability to induce distinct conformational changes in the LBD and accordingly modulate the recruitment of coregulators. Agonists direct a small amphipathic helix (helix 12 of the LBD and part of AF-2) to complete the fold of a hydrophobic pocket, which enables the docking of diverse transcriptional coactivators (7,8). Antagonists and SERMs, like tamox-ifen and raloxifene, block the agonist-dictated positioning of helix 12 and instead allow this helix to dock itself in part of the hydrophobic pocket (7,8). This conformation occludes interactions with coactivators and instead is thought to promote the recruitment of corepressors (9,10). Since SERMs appear to block AF-2, their agonistic properties depend largely on AF-1. Consequently, SERMs act as agonists in contexts where the AF-1 activity is strong (11,12). However, SERMs that differ in their agonistic properties induce distinct conformational changes in the ER␣ LBD (7,8,13), suggesting that SERM-specific LBD conformations are communicated to AF-1. The mechanism of such communication is not clear. As one possibility, ligand binding may affect intramolecular interactions of AF-1 with the LBD (14). Alternatively, the different SERMs may affect differentially interactions with corepressors or enable the recruitment of yet unidentified factors that synergize with AF-1 (13,15,16).
A large number of coactivators that interact with estradiolactivated ER␣ and enable its transcriptional function have been identified (17,18). Coactivators of the p160 steroid receptor coactivator (SRC) family, (SRC-1/NcoA1, GRIP1/TIF2/NcoA2, and pCIP/ACTR/AIB1/RAC3/SRC-3/NcoA3), interact with the AF-2 pocket of the LBD via short amphipathic ␣-helical motifs with the consensus sequence LXXLL, also called NR boxes (19). In addition, SRC coactivators interact with the AF-1 of ER␣ in a ligand-independent manner (20). Thus, in the presence of ER␣ agonists, when both AFs are active, SRC coactivators promote a transcriptional synergism between AF-1 and AF-2 (21,22). In the presence of SERMs, SRC coactivator interactions with AF-1 are thought to promote SERM-induced transcription (6,20,23). Among the SRC family members, SRC-1 in particular has been shown to be important for the agonist activity of tamoxifen in uterine cells, where SRC-1 is expressed at high levels (6). The ability of SRC coactivators to enhance tamoxifen-induced transcription can be inhibited by corepressors (23). These finding have led to the notion that the relative levels or activity of coactivators and/or corepressors may be responsible for the distinct activities of SERMs in different tissues, as well as for the resistance of breast cancers to tamoxifen treatment (6,23,24).
The molecular mechanisms that enable PGC-1␤ to coactivate preferentially ER␣ over other nuclear receptors and to enhance the agonist activity of tamoxifen are not clear. In this study, we elucidate these mechanisms by dissecting the physical and functional interactions of PGC-1␤ with ER␣ and with SRC-1. We identify multiple interaction domains that enable PGC-1␤ to act synergistically with SRC-1 to enhance agonistas well as SERM-dependent ER␣-mediated transcription. Importantly, our findings reveal a role for the ER␣ LBD, and specifically for an AF-2-like surface, in promoting interactions with PGC-1␤ in the presence of tamoxifen. These results suggest that specific AF-2 coactivators, such as PGC-1␤, can recognize the tamoxifen-induced conformation of the ER␣ LBD and contribute to the agonistic properties of tamoxifen.
Cell Culture, Transfections, and Ligands-COS7 and U2OS cells were cultured in Dulbecco's modified Eagle's medium supplemented with 9% fetal bovine serum. Medium lacking phenol red and supplemented with charcoal-stripped or charcoal/dextran-treated (HyClone) fetal bovine serum was used when assaying ligand responses. Cells used for luciferase assays were seeded into 6-well plates 24 h prior to transfection by the calcium phosphate precipitation method. All transfections included 0.2 g of p6RlacZ for normalization of transfection efficiency. Amounts of expression and reporter plasmids per transfection are indicated in the figure legends. After overnight exposure to the DNA-calcium phosphate precipitate, cells were washed and incubated for an additional 24 h in fresh medium containing the indicated ligands. Assays for luciferase and ␤-galactosidase activities were performed as described (31). Luciferase values normalized to ␤-galactosidase activity are referred to as luciferase units. Data shown represent the mean Ϯ S.D., unless otherwise indicated, of at least four values from two independent experiments performed in duplicates. 17␤-estradiol (E2), tamoxifen, and 4-OH-tamoxifen were from Sigma (E8875, T9262, and H7904) and dissolved in 100 or 70% ethanol. The raloxifene analogue LY117018 (dissolved in 100% ethanol) was kindly provided by Lilly.
GST Pull-down Interaction Assay-Expression of GST fusion proteins in the E. coli strain BL21 was induced by the addition of 250 l of 100 mM isopropyl 1-thio-␤-D-galacto-pyranoside to a 50-ml culture that was pregrown at 37°C to an A 600 of around 0.5. The induced culture was then grown for 3 h at room temperature, and the bacteria were harvested by centrifugation, washed once in PBS containing 1 mM phenylmethylsulfonyl fluoride and 1 g/ml aprotinin, leupeptin, and pepstatin (PBS*), frozen in liquid N 2 , and stored at Ϫ70°C. Cells were resuspended in 2.5 ml of PBS*, supplemented with 250 l of freshly prepared lysozyme (10 mg/ml in 50 mM Tris-HCl, pH 8, 2 mM EDTA; Sigma), and incubated for 30 min on ice. Cell lysates were prepared by sonication and then mixed with 125 l of 10% Nonidet P-40 and incubated for 30 min on ice. The cell lysates were transferred to Eppendorf tubes and centrifuged at 14,000 rpm for 30 min at 4°C. The cleared lysates were then incubated for 30 min at room temperature with 50 l of glutathione-Sepharose 4B beads (Amersham Biosciences) that had been washed once with PBS* containing 0.5% Nonidet P-40. The beads were subsequently washed twice with 2 ml of PBS* containing 0.5% Nonidet P-40 and once with 2 ml of Binding Buffer* (20 mM Tris-HCl, pH 8, 75 mM KCl, 3 mM MgCl 2 , 1 mM EDTA, 10% glycerol, 0.1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, and 1 g/ml aprotinin, leupeptin, and pepstatin), resuspended in 0.5 ml of Binding Buffer*, and stored at 4°C. The integrity and amount of the bound GST fusion proteins were determined by SDS-PAGE using different amounts of bovine serum albumin as a standard for protein concentration. The [ 35 S]methionine-labeled in vitro translated proteins were generated by the TNT T7 coupled reticulocyte lysate system (Promega) according to the manufacturer's instructions using EasyTag TM L-[ 35 S]methionine (specific activity 1175 Ci/mmol; PerkinElmer Life Sciences) as label. Labeled in vitro translated protein (5 l) was added to 40 l of beads containing ϳ1 g of GST fusion protein that had been diluted with a 50% slurry of washed empty Sepharose CL-4B beads (Sigma) and 125 l of Binding Buffer* in 1.5-ml screw cap tubes. This mix was incubated for 1 h at room temperature on an end over end tube rotator. The beads were then washed four times with 0.5 ml of Binding Buffer*, and bound proteins were eluted in 30 l of 2ϫ loading buffer, resolved by SDS-PAGE, and visualized by autoradiography.

Efficient Coactivation by PGC-1␤ Requires the AF-1 Domain of ER␣-
The agonist activity of tamoxifen has been attributed to the ability of this ligand to promote the transcriptional function of the AF-1 domain of ER␣ (11,12). Because PGC-1␤ enhances the agonist activity of tamoxifen (26), we reasoned that PGC-1␤ may interact functionally with the AF-1 domain. To test this hypothesis, we compared the ability of PGC-1␤ to coactivate full-length ER␣ versus a variant of ER␣ that lacks AF-1 (ER␣.⌬AF-1). As previously reported, PGC-1␤ expression in COS7 cells enhanced potently the E2-dependent activation of an ERE-driven luciferase reporter by full-length ER␣ (Fig. 1A). This enhancement was significantly lower for the ER␣.⌬AF-1 variant, suggesting that AF-1 is required for an efficient response to PGC-1␤. A similar requirement for AF-1 was seen in HeLa cells (data not shown). Full-length ER␣ and ER␣.⌬AF-1 were expressed at comparable levels, suggesting that differences in expression could not account for the different responses to PGC-1␤ (Fig. 1B). Moreover, a requirement for AF-1 was not evident when ER␣ was coexpressed with a different coactivator, PGC-1␣ (Fig. 1A).
Next, we asked whether the AF-1 of ER␣ was sufficient to convert a nuclear receptor that is poorly coactivated by PGC-1␤, like GR (26), to one that responds efficiently to PGC-1␤. To this end, we replaced the AF-1 of GR with the AF-1 of ER␣ and compared the responses of the chimeric ER␣(AF-1)-GR and of wild-type GR to PGC-1␤. As seen in Fig. 1C, ER␣(AF-1)-GR was coactivated robustly, around 20-fold, by PGC-1␤. In contrast, PGC-1␤ had at most a 2-fold effect on the activity of wild-type GR, as shown previously (26). In conclusion, the AF-1 of ER␣ is not only required for efficient coactivation by PGC-1␤ but can also confer responsiveness to PGC-1␤ when fused to a heterologous receptor DBD and LBD. A, COS7 cells were cotransfected with 1 g of pSG5/ER␣ or pSG5/ER␣.⌬AF-1, 1 g of the luciferase reporter construct p⌬(vERE)x1-Luc, and 0.5 g of either pcDNA3 control vector, pcDNA3/HA-PGC-1␤, or pcDNA3/HA-PGC-1␣. Cells were treated with 50 nM E2 for 24 h and assayed for luciferase activity. B, cell extracts were prepared from COS7 cells transfected with pSG5/ER␣ or pSG5/ER␣.⌬AF-1 and subjected to Western analysis using polyclonal anti-ER␣ antibodies. C, COS7 cells were cotransfected with 1 g of pSG5/GR or pSG5/ER␣(AF-1)-GR, 1 g of the luciferase reporter construct pTAT3-Luc, and 1 g of pcDNA3 control vector or pcDNA3/HA-PGC-1␤. Cells were treated with 50 nM corticosterone for 24 h and assayed for luciferase activity. Data in A and B are expressed as -fold enhancement of nuclear receptor activity by coactivator in the presence of hormone; the activity in the presence of hormone and the absence of coactivator was set equal to 1 for all receptor variants.
The Hinge/AF-2a Region of ER␣ Contributes to the Coactivation of ER␣ by PGC-1␤-Because PGC-1␤ does not interact directly with the AF-1 of ER␣ and yet enhances the activity of tamoxifen-bound ER␣ (26), a context where coactivator interactions with AF-2 are thought to be blocked, we next asked whether PGC-1␤ interacts with other domains of ER␣. Indeed, PGC-1␤ enhanced the activity of the variant ER␣.N341, which includes AF-1, the DBD, the hinge region, and most of AF-2a, a domain (aa 282-351) previously shown to carry an independent activation function (32) (Fig. 3, A and B). A partial deletion (ER␣.N307) or the complete removal of the AF-2a domain (ER␣.N280) abolished responsiveness to PGC-1␤ (Fig. 3B), indicating a role for this region in the coactivation by PGC-1␤. To gain an insight into the mechanism by which this region contributes, we tested the ability of the hinge/AF-2a domain to interact physically with PGC-1␤. As seen in Fig. 3C, in vitro translated PGC-1␤ bound, albeit weakly, to bacterially expressed GST-hinge/AF-2a fusion protein, suggesting a direct physical interaction.
Next, we tested the ability of the hinge/AF-2a domain to confer responsiveness to PGC-1␤ by itself or in combination with other domains of ER␣. To ensure that any activation seen in the presence of PGC-1␤ was mediated by the ER␣ variants we wished to analyze, we performed these assays in the context of ER␣ fusions to the Gal4 DBD, measuring luciferase activity of a Gal4-responsive reporter. PGC-1␤ did not coactivate a Gal4 DBD fusion to just the hinge/AF-2a region (data not shown), suggesting that the PGC-1␤/AF-2a physical interaction is not sufficient by itself. PGC-1␤ did, however, coactivate modestly a Gal4 DBD fusion protein that harbors AF-1 and the hinge/ AF-2a region (AF-1/G4/341; Fig. 3, A and D), suggesting that these two domains together enable responsiveness to PGC-1␤. Moreover, the presence of the hinge/AF-2a region enhanced significantly the ability of PGC-1␤ to coactivate the ER␣ LBD. The -fold activation by which PGC-1␤ enhanced the E2-dependent activity of the ER␣ LBD was higher when the complete hinge/AF-2a region was present (G4/251C) than when its N-terminal part was missing (G4/308C) (Fig. 3, A and E). Finally, we tested the impact of the hinge/AF-2a region in the context of both AF-1 and LBD/AF-2, using Gal4 DBD chimeras that have AF-1 and the LBD either with the hinge/AF-2a region (AF-1/G4/251C) or without it (AF-1/G4/308C) (Fig. 3A). The presence of the hinge/AF-2a region allowed for a much stronger response to PGC-1␤ (Fig. 3F). Notably, the combined presence of AF-1, hinge/AF-2a region, and the LBD/ AF-2 led to a protein whose activity was potently enhanced by PGC-1␤ (Fig. 3F). In conclusion, although the hinge/ AF-2a domain is not sufficient by itself to respond to PGC-1␤, it enables coactivation when together with AF-1 (Fig. 3D) and/or the ER␣ LBD (Fig. 3E).
PGC-1␤ Interacts Physically with the AF-1 Coactivator SRC-1e-Because the AF-1 domain of ER␣ clearly contributes to the response to PGC-1␤, we next considered the possibility that although PGC-1␤ does not bind directly to AF-1, it may interact with an AF-1 coactivator. An appealing candidate is SRC-1, an ER␣ AF-1 coactivator that enables tamoxifen to act as an agonist (6,23) and that interacts physically with the activation domain of the PGC-1␤-related coactivator PGC-1␣ (33). In a mammalian two-hybrid assay, PGC-1␤, like PGC-1␣, interacted with SRC-1e (Fig. 4B). Furthermore, the N-terminal 128 aa of PGC-1␤, expressed as a GST fusion protein in bacteria, interacted in vitro with full-length SRC-1e (Fig. 4C). As control, the activation domain of VP16 that has an acidic nature, like aa 1-128 of PGC-1␤, showed no interactions with SRC-1e (Fig.  4C). To map the regions of SRC-1e that mediate the interaction with PGC-1␤, we tested the ability of different domains of SRC-1e (Fig. 4A) to bind PGC-1␤ in vitro and in a mammalian two-hybrid assay. These studies identified two regions of SRC-1e, aa 254 -422 and 1048 -1140, that interact with PGC-1␤ (Fig. 4, C and D). Next, we asked whether the existence of two binding surfaces for PGC-1␤ is a common feature of p160 family coactivators. Indeed, the corresponding regions of GRIP1 interacted efficiently with PGC-1␤ and PGC-1␣ (Fig. 4E). In conclusion, PGC-1␤ interacts with two distinct regions of the AF-1 coactivator SRC-1e, suggesting that SRC-1 could mediate the functional interaction between PGC-1␤ and the AF-1 domain of ER␣.
PGC-1␤ and SRC-1e Interact Functionally and Coactivate Tamoxifen-bound ER␣-The physical interaction between PGC-1␤ and SRC-1e suggests that the two coactivators may cooperate in enhancing the transcriptional activity of ER␣. To test this notion, we evaluated the effect of PGC-1␤ and SRC-1e coexpression on ER␣ activity in different contexts (Fig. 5). First, we tested the ability of PGC-1␤ to synergize with a variant of SRC-1 that has its three NR boxes mutated and can therefore no longer interact with the AF-2 of ER␣ (SRC-1e.M123) (34). This SRC-1e NR box mutant has similar activity to that of wild-type SRC-1e in the coactivation of ER␣(AF-1) (data not shown), suggesting that it retains interactions with the AF-1 of ER␣. As seen in Fig. 5A, SRC-1e.M123 synergized with PGC-1␤ in the enhancement of E2-activated ER␣ at an ERE-driven luciferase reporter. This effect of SRC-1e.M123 was not seen with an ER␣ variant that lacks the AF-1 (ER␣.⌬AF-1; Fig. 5A), indicating that the PGC-1␤/SRC-1e synergy requires the AF-1 domain.
To further corroborate the synergism between PGC-1␤ and SRC-1, we next tested the effect of these coactivators on the activity of a Gal4DBD fusion protein that bears the AF-1 and hinge/AF-2a domains of ER␣ (AF-1/G4/341; see Fig. 3A). We observed again a synergistic activation when PGC-1␤ and SRC-1e were coexpressed (Fig. 5B), consistent with a functional interaction between PGC-1␤ and SRC-1. Finally, we asked whether the PGC-1␤/SRC-1 interaction could influence the ability of selective modulators, such as tamoxifen and raloxifene, to act as ER␣ agonists. Indeed, we observed a ϳ10-fold activation of tamoxifen-bound AF-1/G4/251C when PGC-1␤ and SRC-1e were coexpressed, whereas PGC-1␤ and SRC-1e alone had a ϳ3and ϳ1.5-fold effect, respectively (Fig. 5C). Interestingly, PGC-1␤ and SRC-1e did not enhance the activity of ER␣ bound to the raloxifene analogue LY117018, a different SERM, suggesting that subtle structural differences in the LBD of ER␣ affect interactions with PGC-1␤ and/or SRC-1e. In conclusion, PGC-1␤ and SRC-1e synergize to enhance the transcriptional activity of tamoxifen-bound ER␣. Notably, coexpression of the two coactivators in COS7 cells, a cell line with inherently low agonist activity of tamoxifen, creates a cellular context where tamoxifen activates ER␣-mediated transcription.
A Role for the ER␣ AF-2 in Tamoxifen Agonist Activity-The fact that the responsiveness of SERM-activated ER␣ to PGC-1␤ is sensitive to subtle differences in the LBD conformation, as seen in tamoxifenversus raloxifene-bound ER␣, prompted us to examine a potential role for the ER␣ LBD, and in particular the AF-2 surface, in the coactivation of tamoxifen-bound ER␣. PGC-1␤ interacts with the AF-2 of ER␣ via two LXXLL-containing motifs, also known as NR boxes (NR1 and NR2) (26). First, we asked whether the two NR boxes are important for the ability of PGC-1␤ to enhance tamoxifen-dependent ER␣ activity. ER␣ activity was assessed in U2OS cells, where PGC-1␤ coactivates tamoxifen-bound AF-1/G4/251C robustly, even in the absence of exogenous SRC-1e, (Fig. 6A), and where PGC-1␤ has been shown to coactivate tamoxifen-bound ER␣ at the C3 promoter (26). In these same cells, PGC-1␤ also coactivates ER␣ stimulated by 4-OH-tamoxifen, the in vivo active metabolite of tamoxifen (Fig. 6B). Interestingly, mutations in the first NR box (nr1 mut) reduced the ability of PGC-1␤ to coactivate tamoxifen-bound AF-1/G4/251C by ϳ50%, whereas mutations in NR box 2 alone (nr2 mut) had no effect (Fig. 6C). The effects of the single NR box mutations on the response to tamoxifen were comparable with the effects of the same mutations on the response to estradiol (Fig. 6C). The double nr1/nr2 mutant activated tamoxifen-bound ER␣ to a similar extent as the nr1 single mutant (ϳ50% of that of wild-type PGC-1␤), suggesting that NR box 2 does not contribute to the tamoxifen response. In contrast, the nr1/ nr2 double mutant was severely deficient in the coactivation of E2-bound receptor, consistent with our previous report that both NR1 and NR2 can mediate the interaction of PGC-1␤ with E2-activated AF-2 (26) (Fig. 6C). Taken together, these findings indicate that PGC-1␤ contains an unusual nuclear receptor interaction surface, NR1, that contributes to the coactivation of tamoxifen-bound ER␣. In contrast, NR2 is similar to other coactivator LXXLL motifs that interact only with bona fide agonist-bound and not with SERM-bound ER␣. Clearly, mutations in NR1 decrease but do not abolish the ability of PGC-1␤ to enhance the agonist activity of tamoxifen. In a search for other important PGC-1␤ domains in this context, we observed that the region C-terminal to aa 426, which does not include known nuclear receptor interaction motifs, is essential for the activation of tamoxifen-bound receptor (Fig.  6C). Notably, deletion of this PGC-1␤ region had only a weak effect on E2-activated receptor, suggesting that it affects selectively the tamoxifen-activated receptor. In conclusion, these experiments show that one of the NR boxes of PGC-1␤, NR1, contributes to tamoxifen-induced as well as E2-induced transcription. Additional PGC-1␤ surfaces, such as the C-terminal part (aa 427-1023) or NR2, interact selectively with the tamoxifen-or E2-bound ER␣, respectively.
To further investigate the contribution of an interaction of PGC-1␤ with a tamoxifen-induced structure of the ER␣ LBD, we next tested the responsiveness of ER␣ variants with specific mutations in the AF-2 domain of the LBD. The K362A mutation (helix 3 of the ER␣ LBD) reduces interactions with selective coactivators and corepressors; the L372R mutation (helix 5) selectively decreases binding of corepressor NR box  peptides; and the L539A/L540A mutation in helix 12 diminishes the interaction with coactivator LXXLL motifs and may lead to increased corepressor binding (13,15,(35)(36)(37). First, we assessed the ligand responses of the different AF-2 mutants in the context of the AF-1/G4/251C chimeric receptor in U2OS cells in the absence of PGC-1␤ (Fig. 7A). The L539A/L540A mutation reduced the already weak response to tamoxifen (by 50%) and almost completely abolished the response to E2. The K362A and L372R mutants showed similar responses to that of wild-type receptor to tamoxifen but differed in their responses to estradiol. K362A showed a strongly reduced although still detectable response to E2 (30-fold lower than that of wild-type receptor), whereas L372R had a slightly increased E2 response. These results indicate that the endogenous U2OS coactivators interact weakly with the E2-bound K362A mutant. Next, we assessed the effect of PGC-1␤ on the ligand-dependent activity of the different ER␣ variants (Fig. 7B). Notably, the ability of PGC-1␤ to coactivate the tamoxifen-bound receptor was clearly decreased for the K362A mutant (2-fold activation, as opposed to 5-and 9.6-fold activation for the wild-type and L539A/ L540A variants, respectively). This finding is consistent with a role for an AF-2-like surface, and in particular Lys 362 , in promoting an interaction with PGC-1␤ in the presence of tamoxifen. Interestingly, PGC-1␤ coactivated the E2-bound K362A variant by more than 1000-fold, thereby recovering the transcriptional activity of K362A in the presence of estradiol to just 3-fold lower than that of wild-type receptor (Fig.  7B, right). The ability of PGC-1␤ to interact with the E2-bound K362A variant depended largely on NR box 1 (Fig. 7C). Altogether, our findings support a role for NR1 of PGC-1␤ and for residue Lys 362 of the AF-2 of ER␣ in the functional interaction of PGC-1␤ with tamoxifen-bound ER␣. Notably, residue Lys 362 , although important for interaction of tamoxifen-bound ER␣ with PGC-1␤, seems dispensable for the interaction of E2-bound ER␣ with PGC-1␤.
The Corepressor Silencing Mediator of Retinoid and Thyroid Hormone Receptor (SMRT) Antagonizes PGC-1␤-mediated Activation of Tamoxifen-bound ER␣-The coactivator/ corepressor ratio has been proposed to determine whether tamoxifen acts as a partial agonist or an antagonist (6,23,24). Moreover, the interaction of ER␣ with corepressors requires a hydrophobic cleft of the ER␣ LBD as well as the hinge region (13, 38, 39) (i.e. surfaces similar to the ones contributing to the interaction with PGC-1␤). To determine the extent to which PGC-1␤ and corepressors act antagonistically to each other, we determined the effect of the corepressor SMRT on the PGC-1␤-mediated enhancement of tamoxifendependent transcription (Fig. 8A). SMRT had no effect on the weak basal activity of the luciferase reporter, either in the absence of the ER␣-Gal4 fusion protein or in the presence of the fusion protein but absence of ligand (data not shown). Tamoxifen by itself was a weak agonist of AF-1/G4/251C (ϳ3.5-fold), and SMRT reduced this transcriptional activity by 50%, consistent with SMRT interacting with the tamoxifen-bound AF-1/ G4/251C. Importantly, coexpression of SMRT reduced dramatically and in a dose-dependent manner the PGC-1␤mediated enhancement of the activity of tamoxifen-bound receptor (Fig. 8, A and B). The negative effect of SMRT on the transcriptional activity of E2-bound receptor was less pro- variants. Cells were treated with 5 M tamoxifen or 50 nM 17␤-estradiol (E2) for 24 h and assayed for luciferase activity. Data are expressed as -fold activation of AF-1/G4/251C by coactivator in the presence of tamoxifen or 17␤-estradiol. nr1 mut is L155/156/159/160A; nr2 mut is L343/346/347A; nr1/2 mut is a combination of nr1 mut and nr2 mut; and N426 is aa 1-426 of PGC-1␤. D, cell extracts from COS7 cells transfected with wild-type pcDNA3/HA-PGC-1␤ or the indicated HA-PGC-1␤ variants were subjected to Western analysis using the anti-HA antibody.
nounced and was similar in the absence and presence of PGC-1␤. These findings suggest that SMRT antagonizes selectively the PGC-1␤-mediated coactivation of tamoxifen-bound receptor, consistent with SMRT and PGC-1␤ acting antagonistic to each other in the context of tamoxifen.

DISCUSSION
The transcriptional activity of nuclear receptors is tuned by ligands and coregulators, which collectively determine the context in which the receptors function (18,40). Despite the wealth of information on the conformational changes that agonists, antagonists, and SERMs confer to the ER␣ LBD, it is still not clear how a specific SERM acts as an agonist in one context and an antagonist in another. One hypothesis is that the distinct ER␣ conformations are recognized selectively by specific coregulators and that the repertoire of the different coregulators in different cells determines the agonist or antagonist capacity of a SERM (5,40). In support of this hypothesis, SERMs can promote interactions of ER␣ with corepressors (13,24,38,41,42). However, we do not know yet of any coactivators that recognize a SERM-bound LBD and contribute to SERM agonist activity. In this study, we show that the ability of PGC-1␤ to promote ligand-activated ER␣ transcription relies on multiple interaction surfaces, among them three surfaces of ER␣: AF-1, the hinge/AF-2a region, and the LBD AF-2. Interaction of PGC-1␤ with AF-1 is indirect and mediated by SRC-1, which synergizes with PGC-1␤ in the coactivation of ER␣. In contrast, PGC-1␤ binds directly the hinge/AF-2a region and AF-2. The interactions of PGC-1␤ with ER␣ via these surfaces facilitate response not only to full agonists, like estradiol, but also to specific SERMs, such as tamoxifen. Surprisingly, one of the LXXLL motifs of PGC-1␤ and part of the AF-2 of the ER␣ LBD contribute to the enhancement of tamoxifen agonist activity, suggesting that PGC-1␤ recognition of the tamoxifen-bound LBD enables part of the agonist activity of tamoxifen.
We have previously shown that the ability of PGC-1␤ to coactivate estradiol-bound ER␣ depends on an interaction between LXXLL motifs (NR1 and NR2 boxes) of PGC-1␤ and the agonist-induced AF-2 domain of ER␣ (26). Nevertheless, PGC-1␤ is a potent coactivator of ER␣ but not of other nuclear receptors that bear similar AF-2 regions, such as ER␤ and GR (26). Our findings in this study explain this apparent paradox by showing that PGC-1␤ coactivates weakly the ER␣ LBD alone, reminiscent of the effect of PGC-1␤ on other receptors (26) and suggesting that AF-2 is important but not sufficient for efficient coactivation. The weak effect of PGC-1␤ via AF-2 is strengthened by two other domains of ER␣: AF-1 and the hinge/AF-2a region. The AF-1 of ER␣ enables coactivation by PGC-1␤ when transferred to a receptor that is not responsive to PGC-1␤, as shown here for GR, consistent with an interaction of AF-1 with PGC-1␤. However, AF-1 by itself does not interact functionally or physically with PGC-1␤, suggesting that other factors (e.g. SRC-1) and ER␣ domains bridge an AF-1 communication with PGC-1␤. In the case of the hinge/AF-2a, the region following the DBD and extending up to aa 341 (i.e. including the AF-2a activation domain) (32) interacts physically with PGC-1␤, albeit weakly, suggesting a role for direct binding and stabilization of a PGC-1␤⅐ER␣ complex. All together, the combined presence of the three ER␣ domains and the bridging factor SRC-1 enables PGC-1␤ to enhance robustly ER␣ transcription. The lack of sequence conservation in AF-1 and hinge regions across nuclear receptors may therefore explain how PGC-1␤ acts selectively on a subset of receptors. The use of multiple weak interaction surfaces that function cooperatively may enable a large degree of flexibility as to when and where PGC-1␤ coactivates ER␣. For example, modifications in AF-1, DNA response element-driven constraints on the presentation of the hinge/AF-2a region, and the levels and availability of bridging factors like SRC-1 would be predicted to impact on the ability of PGC-1␤ to enhance ER␣-mediated responses. Consistent with this notion, the ability of PGC-1␤ to coactivate ER␣ is highly dependent on promoter context (26).
Many coactivators serve as platforms that recruit other coactivators. For example, PGC-1␣ interacts with SRC-1 and the histone acetyltransferases CBP and p300 via its N-terminal activation domain and with the Mediator complex and the arginine methyltransferase PRMT1 via its C-terminal region (33,43,44). It is thus not surprising that PGC-1␤ interacts physically and functionally with SRC-1 and that the two proteins synergize in coactivating ER␣. However, our findings suggest that PGC-1␤ does not act simply as a platform for recruiting SRC-1. The synergism of PGC-1␤ and SRC-1 in the coactivation of ER␣ is strongest when both AF-1, which binds SRC-1 but not PGC-1␤, and the hinge/AF-2a and LBD domains, which bind PGC-1␤, are present (Fig. 5) (data not shown). These results suggest that the two coactivators stabilize each other's interaction with ER␣ and, more specifically, that SRC-1 mediates the functional interaction of PGC-1␤ with the ER␣ AF-1. It is possible that other proteins serve a similar mediating role and stabilize a PGC-1␤ complex with ER␣. As shown here, both PGC-1␤ interaction surfaces of SRC-1 are conserved in other p160 coactivators, such as GRIP1. Notably, these two interaction surfaces are distinct from SRC-1 regions that bind ER␣ (aa 1048 -1140 of SRC-1 do not interact with the ER␣ AF-1) (data not shown), suggesting that SRC-1 could interact simultaneously with PGC-1␤ and ER␣. The PGC-1␤-interacting domains of SRC-1 are, however, subdomains of larger regions shown to interact with other coactivators (CoCoA, CARM1, and PRMT1) and to contribute to the coactivation of nuclear receptors (45)(46)(47). Future studies will be needed to address whether PGC-1␤ competes with these other proteins for binding to SRC-1 or is incorporated together with them into large multicoactivator complexes.
In previous studies, PGC-1␤ but not PGC-1␣ enhanced tamoxifen-induced, ER␣-mediated transcription from the complement C3 promoter in U2OS cells (26). We now demonstrate that PGC-1␤ acts as a coactivator of tamoxifen-bound ER␣, using a chimeric ER␣, where the cognate DBD is replaced by the Gal4 DBD and a minimal synthetic promoter under the control of Gal4 binding sites. The use of this defined system whose activation depends entirely on the chimeric ER␣ is important, because it minimizes any contributions first by transcription factors that may respond to PGC-1␤ and act via other binding sites (e.g. the 1.8-kb C3 promoter fragment contains sites for transcription factors other than ER␣) and, second, by factors other than ER␣ that can act via EREs (e.g. estrogenrelated receptors ␣ and ␥ are coactivated by PGC-1␣ and PGC-1␤ and stimulate transcription via simple EREs (29, 48 -50)). In the defined Gal4-based system, PGC-1␤ acts synergistically with SRC-1 in promoting the agonist activity of tamoxifen. Notably, coexpression of PGC-1␤ and SRC-1 is sufficient to convert COS7 cells, a cell line with inherently low agonist activity of tamoxifen, into a cell line where tamoxifenbound ER␣ activates transcription efficiently. Using the same system, we have also defined the roles of specific PGC-1␤ and ER␣ domains in the response to tamoxifen. In PGC-1␤, the C-terminal region, which seems dispensable for the activation of estradiol-bound ER␣, is essential for the activation of tamoxifen-bound ER␣. In ER␣, the hinge/AF-2a region is important for efficient coactivation by PGC-1␤ (supplemental material). Surprisingly, point mutations in the first PGC-1␤ LXXLL motif and around the AF-2 of ER␣ (i.e. surfaces usually implicated in agonist-dependent interactions) also reduce the ability of PGC-1␤ to activate tamoxifen-bound ER␣, suggesting that PGC-1␤ interacts with the tamoxifen-induced conformation of the ER␣ LBD.
Nuclear receptor ligands with partial agonist activity are thought to induce specific LBD conformations that promote selective interactions with a subset of coregulators (51,52). The ability of tamoxifen to enable the presentation of a protein interaction surface is supported by studies showing that tamox-ifen promotes the interaction of ER␣ with corepressors, which recognize a surface that is similar to the agonist-induced AF-2 pocket (13,14,39,42). Moreover, phage display screens have identified synthetic peptides that interact with the LBD of ER␣ in a tamoxifen-dependent manner (15,16,53). Overexpression of some of these peptides inhibits tamoxifen-induced transcription, presumably by competing with endogenous coactivators that contribute to the agonist activity of tamoxifen (16). However, no coactivators that interact with the tamoxifenbound ER␣ LBD have been identified to date. Two findings in our study suggest that PGC-1␤ is such a coactivator. First, mutations in the PGC-1␤ NR1 box, which mediates interactions with the AF-2 of the ER␣ LBD (26), reduce the ability of PGC-1␤ to coactivate tamoxifen-bound ER␣. Notably, the NR1 box of PGC-1␤ and the corresponding LXXLL motif of PGC-1␣ (L2), which does not enhance tamoxifen agonist activity, share a common core but differ in the flanking sequences. Whereas the L2 motif of PGC-1␣ has prolines in positions Ϫ3 and ϩ8 (numbers relative to the first leucine of LXXLL), the motif of PGC-1␤ (NR1) is flanked by prolines at positions Ϫ8 and ϩ11. Thus, the sequence of NR1 may allow for a longer amphipathic helix, reminiscent of the extended helices of corepressors (54 -56). Second, mutation of Lys 362 of the ER␣ LBD, a conserved residue in nuclear receptors that contributes to binding of both coactivators and corepressors (35, 36, 39, 54 -56), compromises the ability of PGC-1␤ to enhance tamoxifen responses. Strikingly, the K362A mutation does not disrupt the ability of PGC-1␤ to coactivate estradiol-bound ER␣, consistent with PGC-1␤ recognizing similar yet distinct surfaces in tamoxifenand estradiol-bound LBDs. The ability of PGC-1␤ to coactivate efficiently the estradiol-bound K362A ER␣ variant relies on the NR1 motif of PGC-1␤ and is not shared by PGC-1␣ (data not shown), suggesting again that the NR1 of PGC-1␤ has unique properties. All together, our genetic data support a model where both agonists (estradiol) and specific SERMs (tamoxifen) promote interactions of the ER␣ LBD with PGC-1␤, albeit in different ways. The estradiol-bound LBD interacts with NR1 (in a Lys 362 -independent manner) and NR2 (in a Lys 362 -dependent manner), whereas the tamoxifen-bound LBD interacts only with NR1 (in a Lys 362 -dependent manner). Notably, the NR1 box is absent in a splice variant of PGC-1␤ (26), suggesting that alternative splicing may modulate ER␣ responses to agonists and SERMs. The tamoxifen-dependent interaction of ER␣ with PGC-1␤ is currently supported just by genetic data. We have not been able to detect a tamoxifen-dependent physical interaction between the ER␣ LBD and PGC-1␤ using two-hybrid or GST pull-down assays. A possible explanation is that the interaction is weak and stabilized by additional contacts with the hinge/AF-2a region.
Finally, we provide evidence that the corepressor SMRT antagonizes the PGC-1␤-mediated enhancement of tamoxifenbound ER␣ activity. This finding is consistent with the notion that corepressors and PGC-1␤ compete with each other in their interactions with tamoxifen-bound ER␣. It also provides further support to the hypothesis that the relative levels of coactivators and corepressors determine the extent to which SERMs act as agonists (6,23,24). The findings of our study provide a molecular basis for how conformational changes induced by tamoxifen in the ER␣ LBD may promote the interaction of ER␣ with coactivator complexes. SRC-1 interactions with AF-1 are likely to be strengthened by PGC-1␤ interactions with the hinge/AF-2a and an AF-2-like pocket of the LBD as well as interactions of SRC-1 with PGC-1␤. Notably, SRC-1 has been implicated as a key player in determining the agonist activity of tamoxifen in uterine cells (6). Future studies will be required to address potential roles of PGC-1␤ in contributing to tamoxifen agonist activity in physiological systems, such as bone, liver, cardiovascular system, or uterus, or in pathophysiological situations, such as in tamoxifen resistance (i.e. development of tamoxifen agonism) in breast cancer.